Structural Heart Disease

Structural heart diseases include any issues preventing normal cardiovascular function due to damage or alteration to the anatomical components of the heart. This is caused by aging, advanced atherosclerosis, calcification, tissue degeneration, congenital heart defects and heart failure. The most commonly treated areas are the heart valves, in particular the mitral and aortic valves. These can be replaced through open heart surgery or using cath lab-based transcatheter valves or repairs to eliminate regurgitation due to faulty valve leaflets. This includes transcatheter aortic valve replacement (TAVR). Other common procedures include left atrial appendage (LAA) occlusion and closing congenital holes in the heart, such as PFO and ASD. A growing area includes transcatheter mitral repair or replacement and transcatheter tricuspid valve repair and replacement.

RSS icon

Warfarin after TAVR is safe, but fails to boost outcomes

Researchers examined two-year data from transfemoral TAVR patients treated with low-dose aspirin and 30 days of warfarin or just aspirin on its own. 

Thumbnail

EP studies during TAVR are safe and effective, new pilot study confirms

New research in JACC: Cardiovascular Interventions explored the potential of performing EP studies before and after valve deployment. TAVR operators handled all catheter manipulations, and EP specialists were on hand to capture the necessary measurements. 

Thumbnail

NOACs vs. VKAs in TAVR patients with new-onset AFib: New meta-analysis examines key differences

The biggest differences between the two treatment options were major bleeding events and all-cause mortality. There was no significant difference when it came to stroke risk. 

K-Clip Transvascular Tricuspid Repair System from Huihe Healthcare

Cardiologists use new annular clipping device for first time in US to treat severe tricuspid regurgitation

Interventional cardiologists with Henry Ford Health performed the historic procedure on an 85-year-old patient who had been experiencing worsening symptoms for a full year.

PCI

PCI before TAVR fails to improve patient outcomes

“Our results beg the question of whether pre-TAVR baseline coronary angiography is even necessary,” researchers wrote in the American Journal of Cardiology.

Arzhang Fallahi, MD, and David Hsi, MD, discussing imaging-based aortic stenosis screening

Q&A: Cardiologists explore the potential impact of a screening program for aortic stenosis

We already screen patients for breast cancer and lung cancer on a regular basis. Why not establish screening programs for aortic stenosis?

Boston Scientific has received U.S. Food and Drug Administration (FDA) approval for its Watchman FLX Pro left atrial appendage closure (LAAC) device

Boston Scientific gains FDA approval for Watchman FLX Pro LAAC device

This represents the latest iteration of the Watchman technology, which was first approved by the FDA back in 2020. 

Thumbnail

Bleeding events after TAVR: An updated look at a serious side effect

Researchers explored data from more than 2,300 patients, categorizing all bleeding events based on updated VARC-3 definitions. The team's final analysis was published in JACC: Cardiovascular Interventions.

Displaying 217 - 224 of 2332

Around the web

Health Imaging
Use of AI opportunistic screening in CT for cardiovascular disease

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Health Imaging
New imaging protocols proposed to curb rise of cardiovascular infections

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Design by Adaptive Theme
Trimed Popup
Trimed Popup